|
Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions Clinical research trials and Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions. Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions clinical trial. Human subjects often obtain the finest healthcare possible for their Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions  Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions
Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions
For Condition: Multiple Myeloma,Breast Cancer,Prostate Cancer
Status: Recruiting
Sponsor(s): Novartis Pharmaceuticals ,
Synopsis: Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: *Signed informed consent *Greater than 18 years of age *Proof of breast cancer, multiple myeloma or prostate cancer *Diagnosis of at least one cancer-related bone lesion *If patient is of child-bearing potential, negative pregnancy test and on a medically recognized form of contraception *ECOG performance status of 0,1 or 2 *Ability to read, understand and write English or Spanish language *Normal renal function *Corrected serum calcium equal to or greater than 8mg/dl *No clinically symptomatic brain metastases *No known hypersensitivity to Zometa or other bisphosphonates *Not pregnant or lactating
Total Enrollment: 500
Location and Contact Information:
Osceola Cancer Center *Recruiting*
Kissimmee, Florida, 34741
United States
Recruiting Judith Hoskins 407-933-2775
Hematology-Oncology Associates PC *Recruiting*
Albuquerque, New Mexico, 87102
United States
Recruiting Cheryl Reich 505-938-5850
Hematology Oncology Associates, PC *Recruiting*
Medforo, Oregon, 97504
United States
Recruiting Karen Johnson 541-774-5853
Nevada Cancer Center *Recruiting*
Las Vegas, Nevada, 89109
United States
Recruiting Sandy Klimek 702-735-7154
Stockton Hematology Oncology Medical Group *Recruiting*
Stockton, California, 95204
United States
Recruiting Yvonne Bossert 209-466-2626
Virginia Physicians, Inc *Recruiting*
Richmond, Virginia, 23294
United States
Recruiting Shawna Blowe 804-346-1697
New Mexico Oncology Hematology Consultants *Recruiting*
Albuquerque, New Mexico, 87102
United States
Recruiting Debra Harris 505-243-4039
Additional Information:
Study ID Numbers: CZOL446EUS16;
Study Start Date: October 2001
Record last reviewed: December 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00029224
Other Multiple Myeloma Studies:
1. Study of a drug [DCVax (tm)-Prostate] to treat prostate cancer when hormone therapy is no longer effective.
2. To explore racial differences in potential risk factors for developing prostate cancer in the VA population.
3. Treatment With an Investigational Compound for the Prevention of Prostate Cancer
4. Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
5. Selenium and Vitamin E in Preventing Prostate Cancer
Related Studies:
Other Multiple Myeloma Clinical Trials
Other New Mexico Clinical Trials
Other Albuquerque Clinical Trials
Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions
|
|
|
|
|
|
|
|
